Dyadic International, Inc. (DYAI)
NASDAQ: DYAI · Real-Time Price · USD
1.180
-0.030 (-2.48%)
Apr 25, 2025, 4:00 PM EDT - Market closed

Company Description

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally.

It utilizes the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products.

The company offers Dapibus, a protein production platform that enable the rapid development and large-scale manufacture of cost-effective enzymes, proteins, metabolites, and other biologic products for life sciences, food and nutrition, and bioindustrial applications.

In addition, it develops DYAI-100, a C1-SARS-CoV-2 recombinant protein RBD vaccine candidate and first C1, which is in phase 1 clinical trial to produce protein tested in humans.

The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa’s Rubic One Health; joint development agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Dyadic International, Inc.
Dyadic International logo
Country United States
Founded 1979
IPO Date Nov 5, 2004
Industry Biotechnology
Sector Healthcare
Employees 6
CEO Mark Emalfarb

Contact Details

Address:
1044 North U.S. Highway One, Suite 201
Jupiter, Florida 33477-5094
United States
Phone 561 743 8333
Website dyadic.com

Stock Details

Ticker Symbol DYAI
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001213809
CUSIP Number 26745T101
ISIN Number US26745T1016
Employer ID 45-0486747
SIC Code 2836

Key Executives

Name Position
Mark A. Emalfarb Founder, Chief Executive Officer, President and Director
Ping Wang Rawson CPA, M.B.A. Chief Financial Officer
Joseph P. Hazelton Chief Operating Officer
Ana Gómez Rodriguez Secretary of the Board

Latest SEC Filings

Date Type Title
Apr 2, 2025 EFFECT Notice of Effectiveness
Mar 31, 2025 144 Filing
Mar 26, 2025 S-3 Registration statement under Securities Act of 1933
Mar 26, 2025 8-K Current Report
Mar 26, 2025 10-K Annual Report
Mar 20, 2025 8-K Current Report
Feb 6, 2025 SCHEDULE 13G Filing
Dec 20, 2024 144 Filing
Nov 26, 2024 8-K Current Report
Nov 12, 2024 8-K Current Report